샘플 요청 목록

 카트 문의
시장보고서
상품코드
2148457

RNA 간섭(RNAi) 시장

RNA Interference (RNAi)
발행일: | 리서치사: 구분자 Market Glass, Inc. | 페이지 정보: 영문 342 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 7,905,000
PDF & Excel (Team License: Up to 10 users) help
PDF & Excel 보고서를 동일 기업 내 최대 10명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기가 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 이용자 1명당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 11,115 금액 안내 화살표 ￦ 15,019,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 23,715,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 RNA 간섭(RNAi) 시장은 2032년까지 80억 달러에 달할 것으로 전망됩니다.

2025년 33억 달러로 추정되는 RNA 간섭(RNAi) 세계 시장은 2025년부터 2032년까지의 분석 기간 동안 연평균 성장률(CAGR) 13.7%를 기록하며 2032년까지 80억 달러에 달할 것으로 예측됩니다. 본 보고서에서 분석 대상으로 삼고 있는 부문 중 하나인 ‘제품’ 부문은 연평균 성장률(CAGR) 11.5%를 기록하며, 분석 기간이 끝날 때까지 42억 달러에 달할 것으로 예측됩니다. ‘서비스’ 부문의 성장률은 분석 기간 동안 연평균 성장률(CAGR) 16.7%를 나타낼 것으로 추정됩니다.

미국 시장은 8억 8,750만 달러로 추산되는 반면, 중국은 연평균 성장률(CAGR) 17.5%를 나타낼 것으로 예측됩니다.

미국 RNA 간섭(RNAi) 시장은 2025년에 8억 8,750만 달러로 추산됩니다. 세계 2위의 경제 규모를 자랑하는 중국은 2025년부터 2032년까지의 분석 기간 동안 연평균 성장률(CAGR) 17.5%를 기록하며 2032년까지 시장 규모가 17억 달러에 달할 것으로 예측됩니다. 그 밖의 주목할 만한 지역 시장으로는 일본과 캐나다가 꼽히며, 분석 기간 동안 각각 연평균 성장률(CAGR) 10.6% 및 12.4%를 나타낼 것으로 예측됩니다. 유럽 내에서는 독일이 연평균 성장률(CAGR) 약 11.0%를 나타낼 것으로 예측됩니다.

세계 RNA 간섭(RNAi) 시장 - 주요 동향 및 촉진요인 개요

RNA 간섭(RNAi)은 RNA 분자가 유전자 발현을 억제하는 중요한 생물학적 과정으로, 표적이 되는 메신저 RNA(mRNA) 분자를 중화시켜 유전자를 침묵시키는 역할에서 발견된 메커니즘입니다. 유전자의 암호화, 해독, 조절, 발현에 필수적인 RNA는 각각 약 22뉴클레오티드 길이를 가진 두 유형의 소분자 RNA, 즉 소간섭 RNA(siRNA)와 마이크로 RNA(miRNA)를 통해 RNAi를 촉진합니다. siRNA는 특정 mRNA를 특이적으로 표적으로 삼아 침묵시키고 단백질 생성을 차단하도록 설계되어 있으며, 이중가닥 RNA에서 처리되어 절단된 후 세포질로 수송됩니다. 한편, miRNA는 헤어핀 구조로 접힌 단일가닥 RNA에서 유래하며, 단백질 합성을 광범위하게 조절합니다. 이 발견으로 앤드루 파이어와 크레이그 멜로는 2006년에 노벨상을 수상했으며, 이를 통해 RNAi가 유전체 기생체에 대한 자연적인 방어 기전이자 단백질 합성에서 중요한 조절 인자임이 강조되었습니다.

RNAi의 메커니즘은 siRNA나 miRNA가 RNA 유도 침묵 복합체(RISC)를 유도하여 mRNA를 표적으로 삼고, 그 번역을 억제하며 분해를 촉진하는 복잡한 경로를 통해 기능합니다. 이 과정은 mRNA가 단백질 합성에 필요한 수명을 초과하지 않도록 하는 데 매우 중요합니다. RNAi의 치료적 의의는 매우 크며, 분자생물학 분야에서 유전자 발현을 미세하게 조절하고, 유전자 기능 규명 및 약물 표적 검증을 위한 정밀한 도구를 제공합니다. 이 기법은 유전체을 변형하지 않고 기능 규명을 위해 단백질 발현을 저하시키는 ‘노크다운’ 실험에서 특히 유용합니다. 특정 유전자를 선택적으로 억제하는 RNAi의 능력은 질병 관리 분야에서 유력한 후보로 떠오르고 있으며, 기능 장애를 일으키는 단백질을 표적으로 삼음으로써 기존 치료법으로는 어려웠던 질병에 대한 새로운 치료의 길을 열어주고 있습니다.

RNAi 기술은 지질 나노입자를 이용한 RNAi 전달 메커니즘의 개선, 안정적인 RNAi 화합물의 개발, 유전자 표적화 정밀도 향상과 같은 진보에 힘입어 의료 및 농업 양 분야에서 성장의 원동력이 되고 있습니다. CRISPR와 같은 다른 유전체 도구와의 통합을 통해 유전체 연구에서의 유용성은 더욱 높아지고 있습니다. 또한, RNAi의 특이성을 통해 개별 유전적 프로파일에 맞춘 치료가 가능한 맞춤형 의료에 대한 수요가 증가함에 따라, 맞춤형 치료 전략에서의 가능성이 부각되고 있습니다. 농업 분야에서는 수확량 증가, 해충 저항성 향상, 영양가 개선을 갖춘 작물 개발에 RNAi를 적용함으로써 지속 가능한 농업 실천에 기여하고 있음을 입증하고 있습니다. RNAi 기반 치료제에 대한 규제 당국의 승인 및 민관 양측의 막대한 자금 지원으로 인해 RNAi 기술의 도입과 개발이 가속화되고 있으며, 유전자 치료, 신약 개발, 환경의 지속가능성 분야에서 큰 진전이 기대되고 있습니다.

부문:

구성 요소(제품, 서비스), 용도(신약 개발·의약품 개발, 기능 유전체학, 기타 용도), 최종 용도(제약·생명공학 기업, 학술·연구 기관, CRO·CMO)

주요 기업

  • Alnylam Pharmaceuticals, Inc.
  • Benitec BioPharma
  • Ionis Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Qiagen, Inc.
  • Quark Pharmaceuticals, Inc.
  • Silence Therapeutics PLC

해당 분야의 전문가 관점을 바탕으로 합니다. 산업계, 기업, 학계에 걸친 분야 전문가들의 관점을 반영하여, 기존에 발표된 조사 결과 이상의 맥락을 더하고 있습니다.

시장의 초기 신호를 포착합니다 - 기존의 2차 조사에 완전히 반영되기 전에, 전문가 간의 대화, 기업의 동향, 시장과 관련된 논의를 통해 드러나는 변화를 추적합니다.

광범위하고 검증된 정보 기반을 활용합니다 - 컨퍼런스 세션, 기조 연설, 패널 토론, 블로그, 기업 공시 정보, 연차 보고서, 기관 간행물 및 기타 검증된 정보 출처에서 얻은 인사이트를 통합하고 있습니다.

신호와 전략적 시장 방향성을 연결합니다 - 이러한 관점을 통합하여 시장이 어디로 향하고 있는지, 그 움직임을 주도하는 요인은 무엇인지, 그리고 전략에 있어 가장 중요할 가능성이 있는 동향은 무엇인지 파악합니다.

상세한 기업 정보를 제공합니다 - 시장 수준의 분석에 그치지 않고, 경쟁 환경에 참여하며 그 형성에 기여하고 있는 기업을 상세하게 검증합니다.

주요 지역 시장 점유율을 면밀히 검토합니다 - 단일 세계 시장 점유율 수치만으로는 전체적인 상황을 파악하기 어렵습니다. 경쟁 구도는 지역에 따라 크게 다를 수 있습니다. 분석상 관련성이 있는 경우, Market Glass의 보고서는 각 시장의 구조와 동향에 맞추어 상세도를 조정하여 주요 지역 시장 점유율 분석을 심층적으로 다룹니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 26.10.28

Global RNA Interference (RNAi) Market to Reach US$8.0 Billion by 2032

The global market for RNA Interference (RNAi) estimated at US$3.3 Billion in the year 2025, is expected to reach US$8.0 Billion by 2032, growing at a CAGR of 13.7% over the analysis period 2025-2032. Products Component, one of the segments analyzed in the report, is expected to record a 11.5% CAGR and reach US$4.2 Billion by the end of the analysis period. Growth in the Services Component segment is estimated at 16.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$887.5 Million While China is Forecast to Grow at 17.5% CAGR

The RNA Interference (RNAi) market in the U.S. is estimated at US$887.5 Million in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2032 trailing a CAGR of 17.5% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.6% and 12.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.0% CAGR.

Global RNA Interference (RNAi) Market - Key Trends and Drivers Summarized

RNA interference (RNAi) is a vital biological process where RNA molecules inhibit gene expression, a mechanism discovered due to its role in silencing genes by neutralizing targeted messenger RNA (mRNA) molecules. RNA, essential in the coding, decoding, regulation, and expression of genes, facilitates RNAi through two types of small RNA molecules: small interfering RNA (siRNA) and microRNA (miRNA), each about 22 nucleotides long. SiRNAs are engineered to specifically target and silence particular mRNAs, preventing protein production, and are processed from double-stranded RNA, which is cleaved and transported into the cytoplasm. Conversely, miRNAs, originating from single-stranded RNA that folds into hairpin structures, broadly regulate protein synthesis. This discovery, which brought Andrew Fire and Craig Mello the Nobel Prize in 2006, underscored RNAi as a natural defense against genomic parasites and a crucial regulator in protein synthesis.

The RNAi mechanism operates through a complex pathway where siRNAs and miRNAs guide the RNA-induced silencing complex (RISC) to target mRNAs, blocking their translation and signaling their degradation. This process is pivotal for ensuring that mRNAs do not exceed their necessary lifespan in protein synthesis. The therapeutic implications of RNAi are significant, providing a precise tool in molecular biology to fine-tune gene expression for studying gene functions and validating drug targets. This method is particularly valuable in "knockdown" experiments, where protein expression is reduced to investigate function without altering the genome. RNAi's ability to selectively inhibit specific genes makes it a powerful candidate for managing diseases, offering new treatment avenues for conditions traditionally challenging with existing therapies by targeting malfunctioning proteins.

RNAi technology is a growth driver in both medical and agricultural fields, propelled by advancements such as improved RNAi delivery mechanisms using lipid nanoparticles, development of stable RNAi compounds, and enhanced precision in gene targeting. Its integration with other genomic tools like CRISPR enhances its utility in genomic research. Additionally, the rising demand for personalized medicine, where RNAi's specificity can tailor treatments to individual genetic profiles, highlights its potential in custom therapeutic strategies. In agriculture, RNAi's application in developing crops with increased yield, pest resistance, and improved nutritional profiles demonstrates its contribution to sustainable practices. Regulatory approvals for RNAi-based therapeutics and substantial funding from both public and private sectors are accelerating the adoption and development of RNAi technologies, promising significant advancements in gene therapy, drug development, and environmental sustainability.

SCOPE OF STUDY:

The report analyzes the RNA Interference (RNAi) market by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Products Component, Services Component); Application (Drug Discovery & Development Application, Functional Genomics Application, Other Applications); End-Use (Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use, CROs & CMOs End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • Alnylam Pharmaceuticals, Inc.
  • Benitec BioPharma
  • Ionis Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Qiagen, Inc.
  • Quark Pharmaceuticals, Inc.
  • Silence Therapeutics PLC

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • RNA Interference (RNAi) - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 12 Players Worldwide in 2026 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in RNAi Delivery Technologies Expand Addressable Market Opportunity
    • Increasing Investment in RNAi Research and Development Propels Growth
    • Successful Clinical Trials Throws the Spotlight on RNAi Therapeutics
    • Rising Prevalence of Chronic Diseases Drives Adoption of RNAi Solutions
    • Innovations in Nanoparticle Delivery Systems Spur Market Adoption
    • Integration with CRISPR and Gene Editing Technologies Generates Demand
    • Expanding Applications in Oncology and Rare Diseases Sustain Growth
    • Advancements in Bioinformatics and Computational Biology Drive RNAi Research
    • Emergence of RNAi-based Therapeutics for Infectious Diseases Expands Market Opportunities
    • Rising Focus on Personalized Medicine Propels Growth in RNAi Applications
    • Challenges in Off-Target Effects and Safety Impact Adoption
    • Technological Innovations in siRNA and shRNA Constructs Drive Market Adoption
    • Integration with Drug Delivery Platforms Strengthens RNAi Efficacy
    • Cost Reductions in RNA Synthesis and Manufacturing Spur Market Growth
    • Technological Convergence with Other Therapeutic Modalities Expands Market Potential
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 2: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 3: World 13-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 4: World RNA Interference (RNAi) Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for RNA Interference (RNAi) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Products Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Products Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Products Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Services Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Services Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Services Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Drug Discovery & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for Drug Discovery & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for Drug Discovery & Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Functional Genomics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Functional Genomics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Functional Genomics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Academic & Research Institutions End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Academic & Research Institutions End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Academic & Research Institutions End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for CROs & CMOs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for CROs & CMOs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for CROs & CMOs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 30: USA Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 31: USA 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 32: USA Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 33: USA Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 34: USA 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 35: USA Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 36: USA Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 37: USA 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 39: Canada Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 40: Canada 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 41: Canada Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 42: Canada Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 43: Canada 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 44: Canada Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 45: Canada Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 46: Canada 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • JAPAN
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 48: Japan Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 49: Japan 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 50: Japan Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 51: Japan Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 52: Japan 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 53: Japan Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 54: Japan Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 55: Japan 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • CHINA
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 57: China Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 58: China 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 59: China Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 60: China Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 61: China 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 62: China Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 63: China Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 64: China 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • EUROPE
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 66: Europe Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 67: Europe 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 68: Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 69: Europe Historic Review for RNA Interference (RNAi) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 70: Europe 13-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 71: Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 72: Europe Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 73: Europe 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 74: Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 75: Europe Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 76: Europe 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • FRANCE
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 78: France Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 79: France 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 80: France Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 81: France Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 82: France 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 83: France Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 84: France Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 85: France 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • GERMANY
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 87: Germany Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 88: Germany 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 89: Germany Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 90: Germany Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 91: Germany 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 92: Germany Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 93: Germany Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 94: Germany 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 96: Italy Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 97: Italy 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 98: Italy Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Italy Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 100: Italy 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 101: Italy Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Italy Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 103: Italy 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 105: UK Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 106: UK 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 107: UK Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 108: UK Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 109: UK 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 110: UK Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 111: UK Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 112: UK 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 114: Spain Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 115: Spain 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 116: Spain Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 117: Spain Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 118: Spain 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 119: Spain Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 120: Spain Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 121: Spain 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 123: Russia Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 124: Russia 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 125: Russia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 126: Russia Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 127: Russia 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 128: Russia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Russia Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 130: Russia 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 133: Rest of Europe 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 136: Rest of Europe 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 139: Rest of Europe 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for RNA Interference (RNAi) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 142: Asia-Pacific 13-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 145: Asia-Pacific 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 148: Asia-Pacific 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 151: Asia-Pacific 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 153: Australia Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 154: Australia 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 155: Australia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 156: Australia Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 157: Australia 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 158: Australia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 159: Australia Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 160: Australia 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • INDIA
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 162: India Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 163: India 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 164: India Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 165: India Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 166: India 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 167: India Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 168: India Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 169: India 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 171: South Korea Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 172: South Korea 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 174: South Korea Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 175: South Korea 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 177: South Korea Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 178: South Korea 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 189: Latin America Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 190: Latin America 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 192: Latin America Historic Review for RNA Interference (RNAi) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 193: Latin America 13-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 195: Latin America Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 196: Latin America 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 198: Latin America Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 199: Latin America 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 201: Argentina Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 202: Argentina 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 204: Argentina Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 205: Argentina 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Argentina Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 208: Argentina 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Brazil Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 211: Brazil 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Brazil Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 214: Brazil 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 216: Brazil Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 217: Brazil 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 219: Mexico Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 220: Mexico 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 222: Mexico Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 223: Mexico 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 225: Mexico Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 226: Mexico 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 229: Rest of Latin America 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 232: Rest of Latin America 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 235: Rest of Latin America 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 237: Middle East Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 238: Middle East 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 240: Middle East Historic Review for RNA Interference (RNAi) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 241: Middle East 13-Year Perspective for RNA Interference (RNAi) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 243: Middle East Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 244: Middle East 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 246: Middle East Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 247: Middle East 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 249: Iran Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 250: Iran 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 251: Iran Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 252: Iran Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 253: Iran 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 254: Iran Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Iran Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 256: Iran 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 258: Israel Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 259: Israel 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 260: Israel Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Israel Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 262: Israel 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 263: Israel Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 264: Israel Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 265: Israel 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 268: Saudi Arabia 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 271: Saudi Arabia 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 274: Saudi Arabia 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 276: UAE Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 277: UAE 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 278: UAE Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 279: UAE Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 280: UAE 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 281: UAE Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 282: UAE Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 283: UAE 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 286: Rest of Middle East 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 289: Rest of Middle East 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 292: Rest of Middle East 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032
  • AFRICA
    • RNA Interference (RNAi) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 294: Africa Historic Review for RNA Interference (RNAi) by Application - Drug Discovery & Development Application, Functional Genomics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 295: Africa 13-Year Perspective for RNA Interference (RNAi) by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Functional Genomics Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 296: Africa Recent Past, Current & Future Analysis for RNA Interference (RNAi) by Component - Products Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 297: Africa Historic Review for RNA Interference (RNAi) by Component - Products Component and Services Component Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 298: Africa 13-Year Perspective for RNA Interference (RNAi) by Component - Percentage Breakdown of Value Sales for Products Component and Services Component for the Years 2020, 2026 & 2032
    • TABLE 299: Africa Recent Past, Current & Future Analysis for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 300: Africa Historic Review for RNA Interference (RNAi) by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 301: Africa 13-Year Perspective for RNA Interference (RNAi) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutions End-Use and CROs & CMOs End-Use for the Years 2020, 2026 & 2032

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기